Search

Session information—March 25, 2025

Topic'Infections caused by multidrug-resistant (MDR) pathogens in hematological patients.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

Chairs and Members

Chair:
Francesco Buccisano, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy (2021-2024)

Co-Chair:
Sylvie Freeman, Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK (2021-2024)

SWG Executive Board members and terms:

Torsten Haferlach, MLL Munich Leukemia Laboratory, Munich, Germany…

Read more

Chairs and Members

Chair:

Marc H. G. P. Raaijmakers, M. D. , Ph. D.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Chairs and Members

Chair (until 2026)Hermann Einsele, Professor of Hematology and Oncology, University Hospital Würzburg (Germany)

Co-chair (until 2026)Arjan van de Loosdrecht, Professor of Hematology and Immunhematology, Amsterdam UMC (The Netherlands)

SWG Steering Committee members
Jorge Sierra, Professor of Hematology, Hospital Santa Creu I Sant Pau…

Read more